340 Results for "

Integrin beta

" in MedChemExpress (MCE) Product Catalog:
Products (340)

340 Results for "Integrin beta" in MCE Product Catalog:

4
4 Cited Publications
Cat. No.: HY-137561
CAS No.: 2376257-44-0
Purity:  99.67%
Synonyms: PLN-74809
Target:  

Integrin

Research Areas:  

Inflammation/Immunology

Bexotegrast (PLN-74809) is an orally active, potent dual αvβ6/αvβ1 integrin inhibitor with Kd of 5.7 nM and 3.4 nM, respectively. Bexotegrast inhibits αvβ6- and αvβ1-induced TGF-β activation with IC50 values of 29.8 nM and 19.2 nM, respectively. Bexotegrast has antifibrogenic effects and block multiple avenues of TGF-β activation in the fibrotic lung .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-P1408A
Target:  

Integrin

Research Areas:  

Cancer

Obtustatin triacetate is a 41-residue non-RGD disintegrin. Obtustatin triacetate can be isolated from the venom of Vipera lebetina obtusa. Obtustatin triacetate is a potent and selective inhibitor of integrin α1β1 adhesion to type IV collagen. Obtustatin triacetate inhibits angiogenesis and may be used in cancer research .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-108831
CAS No.: 189261-10-7
Purity:  99.10%
Natalizumab (AN100226; BG00002) is a humanized monoclonal IgG4 antibody inhibitor that selectively targets α4 integrin (CD49d). It blocks the interaction of integrins such as α4β1 (VLA-4) with vascular cell adhesion molecule VCAM-1, intercellular adhesion molecule ICAM-1, and fibronectin by competitively binding to the α4 subunit. Natalizumab inhibits the adhesion, retention, and transendothelial migration of immune cells (such as CD4 + T cells), reducing the infiltration of inflammatory cells into the central nervous system or lesion sites, thus exerting anti-inflammatory and immunomodulatory activity. Natalizumab is used in the study of relapsing-remitting multiple sclerosis (RRMS) and also has applications in the study of autoimmune or inflammation-related diseases such as Crohn's disease, B-cell lymphoma, and non-infectious uveitis. Natalizumab can also prevent lymphocytes from entering the central nervous system, thereby preventing acute demyelinating relapses .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-108831A
CAS No.: 189261-10-7
Purity:  98.72%
Synonyms: AN100226; BG00002
Natalizumab (Anti-CD49d) (AN100226; BG00002) Solution is a humanized monoclonal IgG4 antibody inhibitor that selectively targets α4 integrin (CD49d), blocking the interaction of integrins such as α4β1 (VLA-4) with vascular cell adhesion molecule VCAM-1, intercellular adhesion molecule ICAM-1, and fibronectin by competitively binding to the α4 subunit. Natalizumab solution inhibits the adhesion, retention, and transendothelial migration of immune cells (such as CD4 + T cells), reducing the infiltration of inflammatory cells into the central nervous system or lesion sites, thereby exerting anti-inflammatory and immunomodulatory activity. Natalizumab (Anti-CD49d) solution is used in the study of relapsing-remitting multiple sclerosis (RRMS) and is also applied in the research of autoimmune or inflammation-related diseases such as Crohn's disease, B-cell lymphoma, and non-infectious uveitis. Natalizumab (Anti-CD49d) can also prevent lymphocytes from entering the central nervous system, thus preventing acute demyelinating relapses .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P9911
CAS No.: 943609-66-3
Synonyms: Anti-Human lymphocyte α4β7 Integrin, Humanized Antibody; LDP-02; MLN-002

Target:  

Integrin

Research Areas:  

Inflammation/Immunology Cancer

Vedolizumab is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P9911A
CAS No.: 943609-66-3

Target:  

Integrin

Research Areas:  

Inflammation/Immunology

Vedolizumab (anti-α4β7-integrin) is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P1868
CAS No.: 134580-64-6
Synonyms: DGEA peptide
Target:  

Integrin

Research Areas:  

Infection

α2β1 Integrin Ligand Peptide interacts with the α2β1 integrin receptor on the cell membrane and mediates extracellular signals into cells. It is a potential antagonist of collagen receptors .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P1868A
Synonyms: DGEA peptide TFA
Target:  

Integrin

Research Areas:  

Others

α2β1 Integrin Ligand Peptide TFA interacts with the α2β1 integrin receptor on the cell membrane and mediates extracellular signals into cells. It is a potential antagonist of collagen receptors .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-107588
CAS No.: 916734-43-5
Purity:  99.94%
Target:  

Integrin

Research Areas:  

Cardiovascular Disease

TC-I 15 (TC-I-15) is a type of allosteric collagen-binding integrin α2β1 inhibitor, and it also inhibits α1β1 and α11β1. TC-I 15 inhibits platelet adhesion to collagen and thrombus deposition. TC-I 15 prevents the formation of a pre-metastatic microenvironment by inhibiting the uptake of cancer-associated fibroblast (CAF) extracellular vesicles (EVs) by lung fibroblasts, which reduces the metastasis of salivary gland adenocystic carcinoma (SACC) to the lungs in mouse models, .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-78263
CAS No.: 1485-00-3
Synonyms: NSC 170724; 5-(2-Nitrovinyl)benzodioxole
MNS (NSC 170724), the beta-nitrostyrene derivative, is an orally active tyrosine kinase inhibitor, a broad-spectrum antiplatelet agent, and a PANoptosis inhibitor. MNS inhibits Src, Syk, and FAK with IC50 of 27.3, 2.8, and 97.6 μM, respectively. MNS inhibits NLRP3 inflammasome and β1 integrin. MNS completely inhibits U46619, ADP-, arachidonic acid-, collagen-, and thrombin-induced platelet aggregation with IC50 values of 2.1, 4.1, 5.8, 7.0, and 12.7 μM, respectively. MNS is cytotoxic to a variety of cells .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-134130
CAS No.: 2023788-32-9
Purity:  99.80%
Target:  

Integrin

Research Areas:  

Inflammation/Immunology

Integrin modulator 1 is a potent and selective α4β1 integrin agonist, with an IC50 of 9.8 nM for RGD-binding α4β1. Integrin modulator 1 increases cell adhesion mediated by α4β1 integrin, with an EC50 of 12.9 nM .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P9984
CAS No.: 1044758-60-2
Synonyms: rhuMAb beta7; RG7413; PRO145223

Target:  

Integrin

Research Areas:  

Cancer

Etrolizumab (rhuMAb Beta7) is a gut-selective, anti-β7 integrin monoclonal antibody. Etrolizumab is specific targeting of the β7 subunit of α4β7 and αEβ7 integrins with Ki values of 18 nM and 1800 pM for Human α4β7 and Human αEβ7-293, respectively. Etrolizumab can be used in research of inflammatory bowel disease (IBD) .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-19767
CAS No.: 1629249-33-7
GSK 3008348 is a small molecule antagonist of integrin αvβ6 with IC50 values for αvβ6, αvβ1, αvβ3, αvβ5, and αvβ8 are 1.50, 2.83, 12.53, 4.00, and 2.26 nM, respectively. GSK 3008348 can target the αvβ6 integrin, inhibit TGF-β activation, and thereby alleviate the fibrotic process. GSK 3008348 prevents the binding of the foot-and-mouth disease virus (FMDV) to the αvβ6 integrin receptor on the surface of host cells, thereby inhibiting the entry of the virus. GSK 3008348 can be used for research on pulmonary fibrosis and various types of cancer .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-145363
CAS No.: 2615912-33-7
Purity:  99.72%
Target:  

Integrin

Research Areas:  

Cancer

αvβ5 integrin-IN-1 (Compound 12) is a selective αvβ5 inhibitor (pIC50 = 8.2). αvβ5 integrin-IN-1 exhibits 800-fold selectivity for αvβ5 versus αvβ3 .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-19767A
CAS No.: 1629249-40-6
GSK 3008348 hydrochloride is a small molecule antagonist of integrin αvβ6 with IC50 values for αvβ6, αvβ1, αvβ3, αvβ5, and αvβ8 are 1.50, 2.83, 12.53, 4.00, and 2.26 nM, respectively. GSK 3008348 hydrochloride can target the αvβ6 integrin, inhibit TGF-β activation, and thereby alleviate the fibrotic process. GSK 3008348 hydrochloride prevents the binding of the foot-and-mouth disease virus (FMDV) to the αvβ6 integrin receptor on the surface of host cells, thereby inhibiting the entry of the virus. GSK 3008348 hydrochloride can be used for research on pulmonary fibrosis and various types of cancer .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P99333
CAS No.: 558480-40-3
Synonyms: M200; Eos 200-4

Target:  

Integrin

Research Areas:  

Cardiovascular Disease Cancer

Volociximab (M200) is a chimeric human/murine IgG4 antibody IIA1 targeting integrin α5β1 (EC50=0.2 nM). Integrin α5β1 is a major fibronectin receptor involved in angiogenesis. Volociximab has antiangiogenic and antitumor activities and inhibits the proliferation of human umbilical vein vascular endothelial cells (HUVECs) .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-107589
CAS No.: 327613-57-0
Purity:  99.96%
Target:  

Integrin

Research Areas:  

Inflammation/Immunology

BIO5192 is a selective and potent integrin α4β1 (VLA-4) inhibitor (Kd<10 pM). BIO5192 selectively binds to α4β1 (IC50=1.8 nM) over a range of other integrins. BIO5192 results in a 30-fold increase in mobilization of murine hematopoietic stem and progenitors (HSPCs) over basal levels .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-107589A
Purity:  99.96%
Target:  

Integrin

Research Areas:  

Inflammation/Immunology

BIO5192 hydrate is a selective and potent integrin α4β1 (VLA-4) inhibitor (Kd<10 pM). BIO5192 hydrate selectively binds to α4β1 (IC50=1.8 nM) over a range of other integrins. BIO5192 hydrate results in a 30-fold increase in mobilization of murine hematopoietic stem and progenitors (HSPCs) over basal levels .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P2300
CAS No.: 862772-11-0
Synonyms: Cyclo(RGDfC)
Target:  

Integrin

Research Areas:  

Cancer

Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC), a cyclic RGD peptide which has high affinity to αvβ3, can disrupt cell integrin interactions. Cyclo(Arg-Gly-Asp-D-Phe-Cys) inhibits pluripotent marker expression in embryonic stem cells (ESCs) and the tumorigenic potential of mESCs in vivo. Cyclo(Arg-Gly-Asp-D-Phe-Cys) can be used in the research of tumors .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P2300A
Synonyms: Cyclo(RGDfC) TFA
Target:  

Integrin

Research Areas:  

Cancer

Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC) TFA, a cyclic RGD peptide which has high affinity to αvβ3, can disrupt cell integrin interactions. Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA inhibits pluripotent marker expression in embryonic stem cells (ESCs) and the tumorigenic potential of mESCs in vivo. Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA can be used in the research of tumors .
loading...
    loading...